Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fimmers

Showing results (421-430 of 436) with videos related to

Pageof 44
Sort By:
Annals of Neurology|March 13, 2010
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphomaAnnika Juergens, Hendrik Pels, Sabine Rogowski, et al.
Journal of Neuro-Oncology|October 22, 2008
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II studyHendrik Pels, Annika Juergens, Axel Glasmacher, et al.
Cerebellum (London, England)|October 24, 2012
Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrumentH Jacobi, M Rakowicz, R Rola, et al.
JAMA Dermatology|November 10, 2021
Machine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult PatientsLaura Maintz, Thomas Welchowski, Nadine Herrmann, et al.
Neurosurgery|July 19, 2011
Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patientsAntonio Santacroce, Maja Walier, Jean Régis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2020
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [<sup>177</sup>Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, et al.
Trials|December 20, 2022
PrImary decompressive Craniectomy in AneurySmal Subarachnoid hemOrrhage (PICASSO) trial: study protocol for a randomized controlled trialErdem Güresir, Tim Lampmann, Simon Brandecker, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Neurology|February 24, 2010
Responsiveness of different rating instruments in spinocerebellar ataxia patientsT Schmitz-Hübsch, R Fimmers, M Rakowicz, et al.
Pageof 44

Showing results (421-430 of 436) with videos related to

Sort By:
Pageof 44
Annals of Neurology|March 13, 2010
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphomaAnnika Juergens, Hendrik Pels, Sabine Rogowski, et al.
Journal of Neuro-Oncology|October 22, 2008
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II studyHendrik Pels, Annika Juergens, Axel Glasmacher, et al.
Cerebellum (London, England)|October 24, 2012
Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrumentH Jacobi, M Rakowicz, R Rola, et al.
JAMA Dermatology|November 10, 2021
Machine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult PatientsLaura Maintz, Thomas Welchowski, Nadine Herrmann, et al.
Neurosurgery|July 19, 2011
Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patientsAntonio Santacroce, Maja Walier, Jean Régis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2020
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [<sup>177</sup>Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, et al.
Trials|December 20, 2022
PrImary decompressive Craniectomy in AneurySmal Subarachnoid hemOrrhage (PICASSO) trial: study protocol for a randomized controlled trialErdem Güresir, Tim Lampmann, Simon Brandecker, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Neurology|February 24, 2010
Responsiveness of different rating instruments in spinocerebellar ataxia patientsT Schmitz-Hübsch, R Fimmers, M Rakowicz, et al.
Pageof 44